Zhemal Rakhmanova

[Liudmila Fedorova @MD_FedorovaLV]

In our new research https://t.co/5r6eC92aND we found that a low level of CD68+ and CD163+ cells had a negative effect on PFS in patients with r/r cHL, while a low level of M2 (CD163/c-maf+) macrophages improved the prognosis of patients during #nivolumab therapy.

[Kirill Lepik M.D. @lepikurian]

Nivolumab 40 mg disregards bodyweight for the treatment of patients with r/r cHL. ORR 70%, median PFS 18.4 months, median OS not reached. https://t.co/26WenrwBd3 What is your opinion regarding the current ICI treatment regimens in cHL? #Nivo40 #lymsm

[Zhemal Rakhmanova @ZhemalR]

"Учитель, который щедро делится своими знаниями для того, чтобы другие выдавали их за свои, подписывали их своими именами, не так прост. Он ставит себя на одну ступень с Господом Богом, незаметно вселяющим в нас идеи, которые мы с лёгкостью выдаём за свои".

[Zhemal Rakhmanova @ZhemalR]

Today is the second day of #14th_rgmm Rich and bright program and state-of-the-art lectures awaits you. Join us! See information on https://t.co/2vEKk0ARAw

[XV Raisa Gorbacheva Memorial Meeting @15th_rgmm]

Gene and Cellular therapy day has started with a great lecture from Boris Fehse followed by lecture by Dr. Barkhatov on molecular monitoring of HSCT efficiency. #14th_rgmm

[XV Raisa Gorbacheva Memorial Meeting @15th_rgmm]

Dr. Bondarenko has just reported about the experience of using midostaurin in Pavlov university #14th_rgmm

[XV Raisa Gorbacheva Memorial Meeting @15th_rgmm]

Dr. Ivanova is an opinion leader in the treatment of resistant chronic lymphocytic leukemia in Saint Petersburg #14th_rgmm

[Francisco Marty, MD @FranciscoMarty_]

Here is the presentation we gave at #EBMT19 on the Cox analysis of risk factors for clinically-significant #CMV infection in the #letermovir phase 3 prophylaxis trial in allogeneic #HCT.

link to all slides: https://t.co/IMz6u45KEm

#bmtsm #cytomegalovirus #TxID #transplantID

[AlessandroDiga @digangiale92]

"All good things come to an end" and so the #EBMT19. A great hug to all the group of YAs, you're amazing! @ZhemalR @buyurdelli @KaterynaFilone1 @charlottekb1 @SabineValenta @sagarpatel @TSYx

[Zhemal Rakhmanova @ZhemalR]

#EBMT19 was really incredible💫🎆! It was an amazing symphony of science👩‍🔬🧬!
I will miss all of my new friends YA2019🥂 @digangiale92 @KaterynaFilone1 @buyurdelli @charlottekb1 @SabineValenta @sagarpatel @TSYx

[Sylvia Tsang @tsysylvia]

Auf Wiedersehen Frankfurt am Main! 🇩🇪 #EBMT19 has been very special to me, making new friends across the world, learning together and striving to improve!
@TheEBMT @TheEBMT_Nurses @ZhemalR @SabineValenta @digangiale92 @KaterynaFilone1 @buyurdelli @sagarpatel @charlottekb1

[Zhemal Rakhmanova @ZhemalR]

Nice talk of prof. @Mohty_EBMT 👍 on social media session! Full of many useful tips #EBMT19

[Razan Mohty @Razan_Mohty]

Again Dr Nagler emphasize on the importance of MRD negativity before transplant #AML #MRD #EBMT19

[Ann Van de Velde @sanguinebiomab]

Can dasatinib stop the toxicity (CRS) of CAR-T Cells without decreasing their viability like a remote ON/OF control? M. Hudecek clairly explains. #EBMT19

[Bone Marrow Transplantation @BMTjournal]

Sign-up to receive free monthly article alerts from the Bone Marrow Transplantation journal direct to your Inbox! https://t.co/hd5oHEchPa

[Sylvia Tsang @tsysylvia]

There's no better way than spending a great night with #EBMT19 Young Ambassadors with lots of laughter 🍝🍷🍻
@ZhemalR @digangiale92 @KaterynaFilone1 @sagarpatel @buyurdelli @TheEBMT @TheEBMT_Nurses

[EBMT @TheEBMT]

Monday: 1st poster session and guided tour #EBMT19: a lot of one-one discussions with authors!

[Zhemal Rakhmanova @ZhemalR]

Surviving severe VOD. "Don't wait, avert the catastrophe!" Great debates of prof. T. Pagliuca and R. Duarte #EBMT19

[Kateryna Filonenko @KaterynaFilone1]

EBMT young ambassadors are preparing to interview for EBMT TV. #EBMT19 @sagarpatel @ZhemalR @TSYx @SabineValenta @buyurdelli @digangiale92